DP
FHTX icon

Diadema Partners’s Foghorn Therapeutics FHTX Stock Holding History

Diadema Partners’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$327K Sell
66,908
-13,036
-16% -$57.8K 0.04% 123
2026
Q1 		$382K Buy
79,944
+49,314
+161% +$271K 0.07% 117
2025
Q4 		$165K Sell
30,630
-19,370
-39% -$87.8K 0.03% 132
2025
Q3 		$245K Buy
+50,000
New +$265K 0.06% 112

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Diadema Partners's FHTX Position: Q2 2026 in Review

Diadema Partners reduced its Foghorn Therapeutics (FHTX) stake by 16% in Q2 2026, selling an estimated $57.8K and leaving 66,908 shares worth $327K. The position accounts for 0.04% of the portfolio, ranked #123.

Diadema Partners first reported a position in FHTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $382K in Q1 2026. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Diadema Partners held 66,908 shares of Foghorn Therapeutics worth $327K as of Q2 2026.
  • Diadema Partners sold 13,036 Foghorn Therapeutics shares in Q2 2026, an estimated $57.8K.
  • Foghorn Therapeutics made up 0.04% of Diadema Partners's portfolio in Q2 2026, its #123 holding.
  • Diadema Partners first reported a position in Foghorn Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Diadema Partners's Foghorn Therapeutics position peaked at $382K in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.